The recent Article indicated some utility of
Organosilicone Drug Derivatives;
Silicon can be strategically introduced in a molecule to modulate its druglike properties, providing medicinal chemists with an unconventional strategy for replacing a carbon atom.
Silicon can also be introduced to replace other heteroatoms and can act as a surrogate of functional groups such as olefin nd amide as well.
The present Perspective focuses on the opportunities that silicon incorporation offers in drug discovery,
with an emphasis on case studies where introduction of silicon has created a benefit over its analog.
We have tried to highlight all the recent developments in the field and briefly discuss the challenges associated with them.
Citation data is made available by participants in Crossref's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search inSciFinder.
Adam A. SzymaniakChenlong ZhangJohn R. CoombsJames P. MorkenACS Catalysis 2018 Article ASAPOxidative radical divergent Si-incorporation: facile access to Si-containing heterocycles
Yuan Yang, Ren-Jie Song, Yang Li, Xuan-Hui Ouyang, Jin-Heng Li, De-Liang HeChemical Communications 2018 54 (12), 1441-1444
Metrics
+
More Article Metrics 
- COVER STORY
Why can’t the drug industry solve its gender diversity problem?
In early 2016, the financial communications firm LifeSci Advisors found itself with a public relations... - SCIENCE CONCENTRATES
Chematica put to the test
Planning efficient synthetic routes can seem like a dark art or feel like a Herculean labor of literature... - BUSINESS CONCENTRATES
Levi’s to cut chemical use
No one wants to be caught wearing dad jeans. And so while denim trends are always evolving, it’s clear... - POLICY CONCENTRATES
Chemours told to cut fluorocarbon emissions
Chemours is facing costly demands from North Carolina regulators to curb atmospheric releases of fluorinated...
0 件のコメント:
コメントを投稿